255 related articles for article (PubMed ID: 19372219)
1. Mdm2 directs the ubiquitination of beta-arrestin-sequestered cAMP phosphodiesterase-4D5.
Li X; Baillie GS; Houslay MD
J Biol Chem; 2009 Jun; 284(24):16170-16182. PubMed ID: 19372219
[TBL] [Abstract][Full Text] [Related]
2. 1H NMR structural and functional characterisation of a cAMP-specific phosphodiesterase-4D5 (PDE4D5) N-terminal region peptide that disrupts PDE4D5 interaction with the signalling scaffold proteins, beta-arrestin and RACK1.
Smith KJ; Baillie GS; Hyde EI; Li X; Houslay TM; McCahill A; Dunlop AJ; Bolger GB; Klussmann E; Adams DR; Houslay MD
Cell Signal; 2007 Dec; 19(12):2612-24. PubMed ID: 17900862
[TBL] [Abstract][Full Text] [Related]
3. Scanning peptide array analyses identify overlapping binding sites for the signalling scaffold proteins, beta-arrestin and RACK1, in cAMP-specific phosphodiesterase PDE4D5.
Bolger GB; Baillie GS; Li X; Lynch MJ; Herzyk P; Mohamed A; Mitchell LH; McCahill A; Hundsrucker C; Klussmann E; Adams DR; Houslay MD
Biochem J; 2006 Aug; 398(1):23-36. PubMed ID: 16689683
[TBL] [Abstract][Full Text] [Related]
4. RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with beta arrestin to control the protein kinase A/AKAP79-mediated switching of the beta2-adrenergic receptor to activation of ERK in HEK293B2 cells.
Lynch MJ; Baillie GS; Mohamed A; Li X; Maisonneuve C; Klussmann E; van Heeke G; Houslay MD
J Biol Chem; 2005 Sep; 280(39):33178-89. PubMed ID: 16030021
[TBL] [Abstract][Full Text] [Related]
5. Mapping binding sites for the PDE4D5 cAMP-specific phosphodiesterase to the N- and C-domains of beta-arrestin using spot-immobilized peptide arrays.
Baillie GS; Adams DR; Bhari N; Houslay TM; Vadrevu S; Meng D; Li X; Dunlop A; Milligan G; Bolger GB; Klussmann E; Houslay MD
Biochem J; 2007 May; 404(1):71-80. PubMed ID: 17288540
[TBL] [Abstract][Full Text] [Related]
6. The unique amino-terminal region of the PDE4D5 cAMP phosphodiesterase isoform confers preferential interaction with beta-arrestins.
Bolger GB; McCahill A; Huston E; Cheung YF; McSorley T; Baillie GS; Houslay MD
J Biol Chem; 2003 Dec; 278(49):49230-8. PubMed ID: 14500724
[TBL] [Abstract][Full Text] [Related]
7. beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi.
Baillie GS; Sood A; McPhee I; Gall I; Perry SJ; Lefkowitz RJ; Houslay MD
Proc Natl Acad Sci U S A; 2003 Feb; 100(3):940-5. PubMed ID: 12552097
[TBL] [Abstract][Full Text] [Related]
8. Delineation of RAID1, the RACK1 interaction domain located within the unique N-terminal region of the cAMP-specific phosphodiesterase, PDE4D5.
Bolger GB; McCahill A; Yarwood SJ; Steele MR; Warwicker J; Houslay MD
BMC Biochem; 2002 Aug; 3():24. PubMed ID: 12193273
[TBL] [Abstract][Full Text] [Related]
9. cAMP-specific phosphodiesterase-4D5 (PDE4D5) provides a paradigm for understanding the unique non-redundant roles that PDE4 isoforms play in shaping compartmentalized cAMP cell signalling.
Lynch MJ; Baillie GS; Houslay MD
Biochem Soc Trans; 2007 Nov; 35(Pt 5):938-41. PubMed ID: 17956250
[TBL] [Abstract][Full Text] [Related]
10. Interaction with receptor for activated C-kinase 1 (RACK1) sensitizes the phosphodiesterase PDE4D5 towards hydrolysis of cAMP and activation by protein kinase C.
Bird RJ; Baillie GS; Yarwood SJ
Biochem J; 2010 Nov; 432(1):207-16. PubMed ID: 20819076
[TBL] [Abstract][Full Text] [Related]
11. Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin.
Shenoy SK; McDonald PH; Kohout TA; Lefkowitz RJ
Science; 2001 Nov; 294(5545):1307-13. PubMed ID: 11588219
[TBL] [Abstract][Full Text] [Related]
12. Beta-arrestin-dependent signaling and trafficking of 7-transmembrane receptors is reciprocally regulated by the deubiquitinase USP33 and the E3 ligase Mdm2.
Shenoy SK; Modi AS; Shukla AK; Xiao K; Berthouze M; Ahn S; Wilkinson KD; Miller WE; Lefkowitz RJ
Proc Natl Acad Sci U S A; 2009 Apr; 106(16):6650-5. PubMed ID: 19363159
[TBL] [Abstract][Full Text] [Related]
13. RACK1 and β-arrestin2 attenuate dimerization of PDE4 cAMP phosphodiesterase PDE4D5.
Bolger GB
Cell Signal; 2016 Jul; 28(7):706-12. PubMed ID: 26257302
[TBL] [Abstract][Full Text] [Related]
14. Beta-arrestin-recruited phosphodiesterase-4 desensitizes the AKAP79/PKA-mediated switching of beta2-adrenoceptor signalling to activation of ERK.
Houslay MD; Baillie GS
Biochem Soc Trans; 2005 Dec; 33(Pt 6):1333-6. PubMed ID: 16246112
[TBL] [Abstract][Full Text] [Related]
15. Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells. Identification and characterization of a novel PDE4D5 promoter.
Le Jeune IR; Shepherd M; Van Heeke G; Houslay MD; Hall IP
J Biol Chem; 2002 Sep; 277(39):35980-9. PubMed ID: 12121997
[TBL] [Abstract][Full Text] [Related]
16. Trafficking patterns of beta-arrestin and G protein-coupled receptors determined by the kinetics of beta-arrestin deubiquitination.
Shenoy SK; Lefkowitz RJ
J Biol Chem; 2003 Apr; 278(16):14498-506. PubMed ID: 12574160
[TBL] [Abstract][Full Text] [Related]
17. {beta}-Arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase.
Girnita L; Shenoy SK; Sehat B; Vasilcanu R; Girnita A; Lefkowitz RJ; Larsson O
J Biol Chem; 2005 Jul; 280(26):24412-9. PubMed ID: 15878855
[TBL] [Abstract][Full Text] [Related]
18. Nedd4 mediates agonist-dependent ubiquitination, lysosomal targeting, and degradation of the beta2-adrenergic receptor.
Shenoy SK; Xiao K; Venkataramanan V; Snyder PM; Freedman NJ; Weissman AM
J Biol Chem; 2008 Aug; 283(32):22166-76. PubMed ID: 18544533
[TBL] [Abstract][Full Text] [Related]
19. Specific interactions between Epac1, β-arrestin2 and PDE4D5 regulate β-adrenergic receptor subtype differential effects on cardiac hypertrophic signaling.
Berthouze-Duquesnes M; Lucas A; Saulière A; Sin YY; Laurent AC; Galés C; Baillie G; Lezoualc'h F
Cell Signal; 2013 Apr; 25(4):970-80. PubMed ID: 23266473
[TBL] [Abstract][Full Text] [Related]
20. beta-arrestin-1 competitively inhibits insulin-induced ubiquitination and degradation of insulin receptor substrate 1.
Usui I; Imamura T; Huang J; Satoh H; Shenoy SK; Lefkowitz RJ; Hupfeld CJ; Olefsky JM
Mol Cell Biol; 2004 Oct; 24(20):8929-37. PubMed ID: 15456867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
